ADM Korea Inc. (187660.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea

Price
6,050.00 KRW
Market cap
350.82 bn KRW
P/E (2025)
–
P/S (2025)
37.83
Dividend yield
0.00 %
Net margin
-159.92 %
Return on equity (ROE)
-68.89 %
Return on assets (ROA)
-45.22 %

ADM Korea Inc. financials

Fiscal year20242025
Revenue9.74 bn KRW9.27 bn KRW
Gross profit101.25 m KRW33.58 m KRW
Operating income-15.98 bn KRW-7.38 bn KRW
EBIT-17.06 bn KRW-12.94 bn KRW
Net income-20.10 bn KRW-14.83 bn KRW
Diluted EPS – continuing operations-475.02 KRW-255.75 KRW

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About ADM Korea Inc.

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. The company was formerly known as Hyundai ADM Bio Inc. and changed its name to Penetrium Bioscience Inc. in March 2026. Penetrium Bioscience Inc. was founded in 2003 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.